Press releases

Powering breakthrough research using Multiomics

 

 

Multi-Omics collaboration of Singleron and Sciomics

 

Powering breakthrough research using Multiomics

 

Singleron and Sciomics – Collaborating in the pursuit of Precision Medicine


Singleron Biotechnologies and Sciomics have a common goal: Precision Medicine. Their scientific approaches, however, seem to come from two sides of a coin. Consequently, their strategic alliance is expected to reach complementary and interlocking scientific findings in the quest of holistic disease research.


Cologne and Heidelberg, Germany, 30 May 2023

Singleron Biotechnologies, a front-runner in single cell multi-omics sequencing solutions and Sciomics, a first-class provider of explorative proteomic and post translational modification profiling platforms, announce their collaboration to advance Precision Medicine.

Singleron Biotechnologies is an innovative single cell sequencing solution provider with a focus on molecular diagnostics. They apply ground-breaking single cell analysis techniques for clinical diagnosis, drug development, and health management. Sciomics’ powerful proteomic and post-translational modification profiling platform provides in-depth insights on protein levels to clients from biotech and pharma industry and is internally used to develop innovative biomarker signatures.

“At Singleron we believe that single cell sequencing and analysis is vital to understand complex disease mechanisms to evolve increasingly individualized medicine” said Dr. Andreas Schmidt, Senior Vice President of Global Business Development at Singleron. “This new relationship between Singleron and Sciomics offers a synergistic approach to understand the multiple layers of cellular regulation”.

“Over the last decade we developed an efficient and robust platform for profiling protein levels and phosphorylation status.”, said Dr. Christoph Schröder, Chief Executive Officer at Sciomics. “By combining multiple omics technologies, we believe significant advances can be facilitated in the area of precision medicine.”

Together, their strategically combined expertise integrates single cell analyses with cutting-edge technology for biomarkers, profiling pathway activity and soluble markers and is expected to deliver innovative and novel insights accelerating advancements in personalized medicine promoting human health.


About Singleron

Founded in 2018, Singleron develops and commercializes single cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic devices, reagents, software analysis and database solutions that facilitate high-throughput single cell analysis. Singleron’s sample services offer expert execution and generation of high-quality results for academia, clinics, and biotech.

The company currently has offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 2,000 laboratories in hospitals, research institutes, and pharmaceutical companies.


About Sciomics

Sciomics has extensive expertise in the field of biomarker discovery, in vitro and in vivo. Their model system characterisation and disease mechanism profiling use high-content protein and post-translational modification profiling. Currently, this results in over 1,400 analysed proteins by using their proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements combined with Machine Learning assisted data analysis. The high-content and high-throughput platform guarantees robust and reproducible results which can be easily translated into validation and clinical assays. Sciomics serves customers world-wide, focussing on the European and North American market.

 

Media contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

The first step in the journey from imprecise drug therapy to precision medicine - REPO4EU’s Euro / Global Platform for Drug Repurposing

Neckargemünd, 9th August, 2022

 

The biotechnology company Sciomics GmbH, located in Neckargemünd, Germany, today announced its participation in an ambitious joint initiative selected and granted almost €23M by the European Commission as part of the Horizon Europe Programme.

REPO4EU’s ultimate goal is to build and grow an industry-level European online platform for validated precision drug repurposing with a global reach. This platform will operate as the go-to data hub for key information, training resources, matchmaking and cooperation in drug repurposing.

The platform will provide extensive expertise throughout the whole value chain in drug repurposing: from freedom-to-operate analysis to intellectual property protection and business development, health technology assessment, ethics and data governance considerations.  

During the next 7 years, 28 partners from 10 countries (The Netherlands, Germany, Austria, Spain, Sweden, Romania, Belgium, Portugal, Switzerland and the United States) will join forces to make REPO4EU a reality and create a unique platform for drug repurposing, pooling stakeholders and expertise at a global stage to create a “made in Europe”, fully-fledged infrastructure for drug repurposing. Sciomics will contribute to the initiative with its expertise and scioDiscover platform for protein biomarker discovery and verification as well as disease mechanism elucidation.

 

Drug repurposing 

But what exactly is drug repurposing? To answer this question, there is first a need to address the elephant in the room: to this day, we still rely on 19th century disease definitions – often named after specific organs, symptoms or even doctors –, when it has become painfully obvious that trying to compartmentalize the human body into small, completely isolated parts with no connection to one another is an extremely naïve endeavour.  

The truth is that our disease definitions are no longer valid – and the end of medicine as we know it is quickly approaching.  

Even though we have witnessed an exponential increase in the volume of drug discovery investments since the 80s, overall efficacy has stagnated in the pharmaceutical sector – there is currently no way of differentiating between patients who will benefit and those who will not, and unwanted side effects cannot be predicted reliably.  

The reason? There is a conceptual problem in how we define diseases and, consequently, in the way we currently approach drug development. Most underlying disease mechanisms are not understood and are thus rather treated symptomatically in an imprecise manner. 

 

Systems Medicine is organ-agnostic 

This philosophy lies at the core of what we call systems medicine: the ambition to map the full network of human diseases – the so-called diseasome – to unravel the hidden connections between mechanistically similar diseases. In the diseasome, diseases appear in clusters, indicating a common genetic origin through shared risk genes. These clusters radically change what we call a disease: now, the underlying causal molecular mechanism becomes our disease definition.

It all comes down to a very simple thought: if we can understand the underlying mechanisms that govern a specific disease, surely, we can repurpose drugs for another disease that shares some of those common elements?  

The answer is yes! Mechanism-based drug repurposing will revolutionize the way we approach drugs – it will help us find new uses for already registered drugs, increase precision and radically cut down on costs and time in the drug development process – jumping straight into clinical trials that are small, precise, innovatively designed and compliant with the highest safety and operational excellence standards.  

 

Curing diseases with high precision 

Chronic diseases are only chronic because we do not know how to cure them yet. REPO4EU’s organ-agnostic approach will push drug repurposing to its full potential by mixing Big Data, Artificial Intelligence-driven bioinformatics and Network Science with advanced cheminformatics to redefine diseases in a mechanism-based manner and repurpose drugs beyond their original target. 

REPO4EU will thereby unlock unprecedented breakthroughs in precision, efficacy and cost-effectiveness, de-risking drug repurposing and paving the way towards personalized therapies and ultimately, precision medicine.  

A resource for researchers, companies, healthcare providers, payers, and patients 

Whether you need to secure bioinformatics support for an unmet medical need, explore a registered compound or a specific mechanism; assess your freedom to operate, outline a patenting strategy or browse regulatory advice; liaise with a business partner, locate a clinical trial test site for phase I-III or craft a business plan... we have the experts and the experience to help you! 

RExPO22 - The 1st International Conference on Drug Repurposing 

REPO4EU will officially start this September, and what better way to kick things off than with a high-profile conference? We are delighted to present RExPO22, the very first instalment in our RExPO series of international conferences on drug repurposing.  

Networking has always been the prime focus of any scientific and business event and this one is both: high impact science and innovative business. Come join us September 2nd-3rd at Maastricht for two days of vibrant keynotes from world-renowned experts and busy discussion around the future of drug repurposing! 

 

Key contacts 

Coordinator: Prof. Dr. Harald HHW Schmidt, Maastricht University, This email address is being protected from spambots. You need JavaScript enabled to view it.

Sciomics: Dr. Christoph Schröder, Sciomics GmbH, This email address is being protected from spambots. You need JavaScript enabled to view it.

Communication: Diana Lopez, AUSTRALO, This email address is being protected from spambots. You need JavaScript enabled to view it.  

Project management office: Miriam Simon, concentris, This email address is being protected from spambots. You need JavaScript enabled to view it.

 

More Information:

REPO4EU initiative: https://repo4.eu
RExPO22 conference: https://repo4.eu/rexpo22-conference/ cropped repo4eu header 1 1

Sciomics participates in collaborative clinical trials for the treatment of metaphyseal chondrodysplasia type Schmid (MCDS)

See below for German version

Heidelberg, 12th February, 2018

 

Multinational consortium has been granted 5.7 Million Euro for the development of novel therapeutic approaches in rare skeletal disorders. Sciomics' expertise with the antibody microarray technology herein serves as a valuable tool for biomarker identification and personalized treatment monitoring.

The biotechnology company Sciomics GmbH, located in Heidelberg, Germany, today announced its participation in the multinational clinical project 'MCDS Therapy'. This five-year collaborative study comprises both world-renowned clinical centres as well as small and medium-sized enterprises in the EU and Australia with a total funding of 5.7 Million Euro. In successive clinical trials, the re-purposing of the drug carbamazepine (CBZ) for the treatment of the skeletal disease metaphyseal chondrodysplasia type Schmid (MCDS) will be investigated. Furthermore, 'MCDS Therapy' encompasses biomarker development and health economics assessment studies to deliver an innovative and affordable therapy for MCDS, along with diagnostic and prognostic tools to personalize the treatment.

MCDS is a skeletal disorder resulting in short stature, abnormally shortened or bowed limbs, chronic pain and decreased mobility. Less than 1 in 100,000 people is affected, which renders the disease a so-called orphan disease. The disease is incurable, and MCDS patients rely on the long-term use of pain therapy and usually undergo numerous orthopaedic surgical interventions to correct knee and hip deformities. This burden in pain and disability leads to poor quality of life and extensive healthcare costs.

CBZ received orphan drug designation by the European Commission for the treatment of MCDS in 2016. 'MCDS Therapy' aims at advancing the re-purposing of CBZ to deliver the first non-surgical therapeutic intervention for MCDS. During the course of the project, an assessment of relevant biomarkers will be incorporated. The aim is to discover novel biomarkers that are directly relevant to CBZ treatment of MCDS which can then be used to monitor therapy and are potentially applicable to a broader group of genetic skeletal diseases or human connective tissue disease in general. 'MCDS Therapy' will use a high-content screening approaches to discover panels of potential biomarkers using samples from both mouse models and patient-derived samples. Herein, Sciomics' antibody microarrays serve as a crucial tool to identify and validate biomarkers for diagnosis, prognosis and personalized therapy.

Sciomics GmbH was founded in 2013 as a spin-off company of the German Cancer Research Centre (DKFZ). 'We are glad to participate in this highly innovative project with our solid expertise in antibody microarrays', states Dr. Christoph Schroeder, CEO of Sciomics. 'Accounting for the hallmarks of our microarray technology, which include high throughput, flexibility, multiplex analysis and robustness, I am convinced that our contribution to this novel treatment option for MCDS will be of great service. Especially for the patients suffering from this severe illness.'

> Download press release as PDF-file

 

 

Heidelberg, 12. Februar 2018

Sciomics an klinischen Studien für die Behandlung von Metaphysärer Chondrodysplasie Typ Schmid (MCDS) beteiligt

Multinationales Konsortium mit einem Gesamtbudget von 5,7 Millionen Euro entwickelt neue therapeutische Ansätze für seltene Knochenerkrankungen. Hierbei spielen die Antikörper-Microarrays von Sciomics eine zentrale Rolle bei der Identifizierung von Biomarkern und Personalisierung der Therapie.

Das Biotechnologie-Unternehmen Sciomics GmbH mit Sitz in Heidelberg teilte heute seine Beteiligung an dem multinationalen klinischen Projekt „MCDS Therapy” mit. An dem Kooperationprojekt mit einem Gesamtbudget von 5,7 Millionen Euro über fünf Jahre arbeiten sowohl renommierte klinische Zentren als auch kleinere und mittelständische Unternehmen aus der EU und Australien mit. In mehreren klinischen Studien soll hierbei die Verwendung des Medikamentes Carbamazepin (CBZ) zur Behandlung der Knochenerkrankung Metaphysäre Chondrodysplasie Typ Schmid (MCDS) untersucht werden. Ein wichtiger Teil der Studien ist die Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie sowie gesundheitswirtschaftliche Aspekte, um eine innovative und kostengünstige Therapie für MCDS zu entwickeln.

MCDS ist eine Knochenerkrankung, deren Symptome Kleinwüchsigkeit, verkürzte und gekrümmte Extremitäten, chronische Schmerzen und eine eingeschränkte Beweglichkeit sind. Weniger als eine von 100.000 Personen ist davon betroffen; es handelt sich bei MCDS somit um eine sogenannte „Orphan Disease“. Die Krankheit ist unheilbar; MCDS-Patienten sind somit ihr Leben lang auf Schmerztherapie sowie orthopädische Behandlung angewiesen. Die chronischen Schmerzen und Behinderungen führen bei den Patienten zu einer geringen Lebensqualität und hohen Behandlungskosten.

CBZ hat 2016 die „Orphan Drug Designation“ der Europäischen Kommission für MCDS erhalten. Ziel von „MCDS Therapy“ ist es, mit der Verwendung von CBZ die erste nicht-invasive Therapie für MCDS zu entwickeln.Ein wichtiger Aspekt des Projekts ist die Identifizierung und Validierung von Biomarkern, die eine direkte Relevanz für die CBZ-Behandlung von MCDS haben. Diese könnten für die Therapieüberwachung von MCDS eingesetzt werden und möglicherweise auch auf andere genetisch bedingte Knochen- und Bindegewebserkrankungen übertragen werden. Im Zuge von „MCDS Therapy“ werden sowohl Proben aus Mausmodellen, als auch von MCDS-Patienten untersucht. Hierbei dienen die Antikörper-Microarrays von Sciomics als wichtige Werkzeuge bei der Identifizierung und Validierung von Biomarkern für Diagnose, Prognose und personalisierte Therapie.

Sciomics wurde 2013 als Spin-Off des Deutschen Krebsforschungszentrums (DKFZ) gegründet. „Wir freuen uns sehr, mit unserer langjährigen Microarray-Expertise zu diesem hochinnovativen Projekt beitragen zu können“, sagt Dr. Christoph Schröder, Geschäftsführer der Sciomics GmbH. „Angesichts der Vorteile unserer Antikörper-Microarrays, wie hoher Durchsatz, Flexibilität, hochparallele Analyse und Reproduzierbarkeit, werden wir einen wichtigen Beitrag zu neuen Therapieoptionen für MCDS leisten.”

 

> Pressemitteilung als PDF

 

Sciomics GmbH
Dr. Christoph Schröder
Im Neuenheimer Feld 583
D-69120 Heidelberg
Germany

Phone: +49 (0) 6221 42948-30
Fax : +49 (0) 6221 42948-34
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: http://www.sciomics.de

Neuro-Sys and Sciomics announce Partnership Agreement

Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.

A NEW STEP FORWARD IN NEURODEGENERATIVE DISEASE RESEARCH

Announcement : Neuro-Sys and Sciomics announce a collaboration to co-develop an unrivaled integrated preclinical solution in neurodegenerative disorders.

December 18, 2019 06:57 PM Eastern Standard Time

GARDANNE, France and HEIDELBERG, Germany – The French biotech company Neuro-Sys SAS and the German biotech company Sciomics GmbH today announced that they are joining their R&D forces to study the proteome and the phosphoproteome in preclinical models of Alzheimer’s, Parkinson’s and ALS diseases to investigate the proteomic and phosphoproteomic profile of these disease models. The aim is to better understand the mechanisms involved in the neurodegenerative process and to provide new solutions for characterizing the efficacy and mode-of-action of neuroprotective compounds.
The changes in the proteome (protein level) and phosphoproteome (phosphorylation status of proteins) will be determined by the scioPhospho platform using advanced in vitro models of Alzheimer’s disease (focused on the chronic and the acute toxicity of the beta amyloid oligomers, AβO), Parkinson’s disease (with a specific attention to the mitochondrial disorders), and amyotrophic lateral sclerosis (focused on the hypersensitivity to glutamate stressor). In addition, the inflammatory component will be analyzed (cytokine release profile).
Identified proteomic changes will be correlated with neuronal survival and proteinopathies detected by immunostaining (e.g. hyperphosphorylation of Tau ; alpha-synuclein aggregation ; translocation of TDP-43).
“For many years, we have been thoroughly investigating the mechanisms occurring in these neurodegenerative diseases. We have developed advanced in vitro models of these diseases in which the mechanisms and the pathways involved in the process of death are carefully studied through our intensive internal research and partnerships”, said Noelle Callizot, PharmD, Ph.D., Chief Scientific Officer at Neuro-Sys. “We believe that the collaboration with Sciomics is a great opportunity to better understand pathophysiological pathways and to help our partners in the development of new therapeutic approaches.”
“Over the last decade we have developed an efficient and robust platform for profiling protein levels and phosphorylation status.”, said Dr. Christoph Schröder, Chief Executive Officer at Sciomics. “By a combination of the profound expertise and advanced pre-clinical models of Neuro-Sys with our in-depth protein readout options, we are looking forward to foster novel insights and developments in the important field of neurodegenerative disorders.”

Preliminary results are expected to be released early 2020.

About Neuro-Sys

Neuro-Sys is an expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action. With a great team of experts and an innovative proprietary automated medium throughput platform combined with advanced models, it provides reliable results and a unique approach in the neurodegenerative diseases research.
The company’s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution.

Contact
Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +33 4 1341 5171
http://www.neuro-sys.com

About Sciomics

Sciomics has extensive expertise in the area of biomarker discovery, in vitro as well as in vivo model system characterisation and disease mechanism profiling using its high-content protein and post-translational modification profiling platform in an analysis service setting and for internal research. More than 1,000 proteins are currently analysed by the proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements. Information on the protein abundance can be combined with the phosphorylation, ubiquitination or methylation status of these proteins. The high-content and high-throughput platform guarantees robust and reproducible results which – due to its immuno-based nature - can easily be translated into validation as well as clinical assays.
The platform’s main applications are the discovery of protein biomarkers, screening and verification of new drug targets, pathway activity profiling as well as drug mode-of-action analysis.

Contact
Email : This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +49 6221 4294830
http://www.sciomics.de

 

PEPperPRINT and Sciomics announce Partnership Agreement

 

Heidelberg, 18th November, 2014

 

Sciomics and PEPperPRINT agreed on a partnership for the co-distribution and co-marketing of their product and service portfolios with the aim to provide a comprehensive microarray toolbox for antibody characterization and biomarker discovery.

 

A joint two-step process for antibody characterization will enable the selection of the optimal antibody from a set of antibody candidates for therapeutic, diagnostic or research purposes. Sciomics will offer its custom antibody microarray platform as well as protein arrays for target binding validation and cross-reactivity analysis. Selected candidates will be further characterized by epitope mapping and epitope substitution scans provided by PEPperPRINT to identify conserved and variable amino acids as well as possible cross-reactions from a bioinformatics analysis of conserved core motifs.

 

The combination of peptide and antibody microarrays by PEPperPRINT and Sciomics further provides a powerful approach for discovery, in-depth characterization and validation of new serum biomarkers including antibodies and serum proteins. A combination of the core strengths of the respective platforms enables a robust and cost-efficient discovery of protein as well as autoantibody biomarker candidates in a highly multiplexed fashion. This increases the likelihood of identifying the optimal biomarker candidates and furthermore can increase the assay accuracy by combining information derived from both platforms.

 

“The partnership agreement is based on a long lasting research relationship and highest appreciation of Sciomics scientific competences. A combination of the core technologies of both companies allows customers to benefit from our complementary and powerful microarray tool box” says Dr. Volker Stadler, CEO of PEPperPRINT. “The fact that both companies are located in Heidelberg certainly facilitates logistics and scientific collaboration and underlines the strength of the Heidelberg biotech cluster.”

 

"Sciomics is very glad to have entered into a partnership with PEPperPRINT. This complements our own expertise and portfolio in antibody characterization with the strong expertise of the PEPperPRINT team." says Dr. Christoph Schröder, CEO of Sciomics. "For biomarker research, combining the powerful microarray platforms of PEPperPRINT and Sciomics enables a most comprehensive coverage of all topics concerning discovery, verification as well as in-depth characterization of biomarker candidates. This partnership enables us to provide the maximum amount of value to our customer's projects."

 

Click here for Press Release as pdf-file.

 

 

 

 

PEPperPRINT
Dr. Lisa Steinbrück
Head of Business Development
Rischerstr. 12
D-69123 Heidelberg
Germany

Phone: +49 (0)6221 72644-89
Fax : +49 (0)6221 72644-75
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: www.pepperprint.com

Sciomics GmbH
Dr. Ronny Schmidt
Business Development
Schneidmühlstr. 19
D-69115 Heidelberg
Germany

Phone: +49 (0) 6221 3283140
Fax : +49 (0) 6221 4294834
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: http://www.sciomics.de